# US 2019/0314545 A1 · Therapeutic agent for solid cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314545 A1
- Document ID: US20190314545A1
- Status: Published application
- Kind: A1
- Application number: 16/315,756
- Filed: 2017-07-07
- Published: 2019-10-17
- Earliest claimed: 2016-07-08
- Assignees: Yanchers Inc.
- Applicants: Yanchers Inc.
- Inventors: Junichi SHIMADA
- Web page: https://patentgrep.com/patent/US20190314545A1

## CPC

- A61L 24/06: obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)}
- A61B 6/00: Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment (instruments measuring radiation intensity for application in the field of nuclear medicine, e.g. in vivo counting, G01T1/161)
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/695: Silicon compounds
- A61K 31/785: Polymers containing nitrogen
- A61K 49/0438: {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}
- A61K 49/0447: {Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound}
- A61P 35/00: Antineoplastic agents
- A61L 2400/06: Flowable or injectable implant compositions
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel therapeutic agent for solid cancer capable of hardening the cellular tissue itself of a solid cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue, is disclosed. The therapeutic agent for solid cancer is composed of a liquid composition containing as an active component an ethoxy-containing compound capable of undergoing polycondensation in a cellular tissue. The therapeutic agent for solid cancer is capable of hardening the cellular tissue itself of a solid cancer such as lung cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue. In conventional therapeutic methods, the risk of metastasis due to spreading of cancer cells through the bloodstream cannot be eliminated. In contrast, this therapeutic agent for solid cancer instantly surrounds cancer cells, so that the risk of metastasis can be largely reduced.

## Claims

### Claim 1

A therapeutic agent for solid cancer, composed of a liquid composition containing as an active component an ethoxy-containing compound capable of undergoing polycondensation in a cellular tissue.

### Claim 2 (depends on 1)

The therapeutic agent for solid cancer according to claim 1, wherein said ethoxy-containing compound is an ethoxy-containing silicon compound.

### Claim 3 (depends on 2)

The therapeutic agent for solid cancer according to claim 2, wherein said ethoxy-containing silicon compound is an ethoxysilane compound.

### Claim 4 (depends on 3)

The therapeutic agent for solid cancer according to claim 3, wherein said ethoxysilane compound is at least one selected from the group consisting of ethyl silicate and condensates thereof, and methyltriethoxysilane and condensates thereof.

### Claim 5 (depends on 1)

The therapeutic agent for solid cancer according to claim 1, further comprising a cyanoacrylate-based monomer.

### Claim 6 (depends on 5)

The therapeutic agent for solid cancer according to claim 5, wherein said cyanoacrylate-based monomer is at least one selected from the group consisting of methyl 2-cyanoacrylate, ethyl 2-cyanoacrylate, iso-propyl 2-cyanoacrylate, n-propyl 2-cyanoacrylate, n-butyl 2-cyanoacrylate, iso-butyl 2-cyanoacrylate, t-butyl 2-cyanoacrylate, hexyl 2-cyanoacrylate, ethoxyethyl 2-cyanoacrylate, octyl 2-cyanoacrylate, and bis(alkylene 2-cyanoacrylate) compounds.

### Claim 7 (depends on 2)

The therapeutic agent for solid cancer according to claim 2, further comprising a transition metal ethoxide.

### Claim 8 (depends on 7)

The therapeutic agent for solid cancer according to claim 7, wherein said transition metal ethoxide is titanium ethoxide.

### Claim 9 (depends on 1)

The therapeutic agent for solid cancer according to claim 1, further comprising an X-ray contrast agent or an MM contrast agent.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method of treating a solid cancer, comprising administering the liquid composition recited in claim 1 to a cancer tissue of a solid cancer patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein said ethoxy-containing compound is an ethoxy-containing silicon compound.

### Claim 14 (depends on 13)

The method of claim 13, wherein said ethoxy-containing silicon compound is an ethoxysilane compound.

### Claim 15 (depends on 14)

The method of claim 14, wherein said ethoxysilane compound is at least one selected from the group consisting of ethyl silicate and condensates thereof, and methyltriethoxysilane and condensates thereof.

### Claim 16 (depends on 12)

The method of claim 12, wherein said therapeutic agent further comprises a cyanoacrylate-based monomer.

### Claim 17 (depends on 16)

The method of claim 16, wherein said cyanoacrylate-based monomer is at least one selected from the group consisting of methyl 2-cyanoacrylate, ethyl 2-cyanoacrylate, iso-propyl 2-cyanoacrylate, n-propyl 2-cyanoacrylate, n-butyl 2-cyanoacrylate, iso-butyl 2-cyanoacrylate, t-butyl 2-cyanoacrylate, hexyl 2-cyanoacrylate, ethoxyethyl 2-cyanoacrylate, octyl 2-cyanoacrylate, and bis(alkylene 2-cyanoacrylate) compounds.

### Claim 18 (depends on 13)

The method of claim 13, further comprising a transition metal ethoxide.

### Claim 19 (depends on 18)

The method of claim 18, wherein said transition metal ethoxide is titanium ethoxide.

### Claim 20 (depends on 12)

The method of claim 12, wherein said therapeutic agent further comprises an X-ray contrast agent or an MRI contrast agent.

### Claim 21 (depends on 12)

The method of claim 12, wherein said solid cancer is lung cancer.
